Information Provided By: 
Fly News Breaks for September 21, 2018
GTXI
Sep 21, 2018 | 11:21 EDT
As previously reported, Stifel analyst Adam Walsh downgraded GTx to Hold from Buy after the Phase 2b ASTRID trial evaluating enobosarm in women with SUI did not achieve statistical significance on its primary endpoint. Following the trial failure, Walsh would expect the SUI program to be discontinued and for the stock to trade at or around cash levels of about $2 per share. Accordingly, the analyst lowered his price target on GTx shares to $2 from $45.
News For GTXI From the Last 2 Days
There are no results for your query GTXI
